Susan M. Domchek, MD
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated encouraging activity in patients with HER2-negative metastatic breast cancer with germline BRCA
mutations, prompting an expansion cohort within the open-label phase II MEDIOLA trial, explained lead study investigator Susan Domchek, MD.
Following a 4-week run in, in which patients received 300 mg of olaparib monotherapy twice daily, patients continued on olaparib at the prespecified dose and were given 1.5 g of intravenous durvalumab every 4 weeks.
... to read the full story